Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Del Galdo

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
Cell Cycle (Georgetown, Tex.)|November 5, 2011
Caveolin-1: a new therapeutic target in tissue fibrosis and scleroderma?Francesco Del Galdo
The Lancet. Rheumatology|January 26, 2024
New lessons for an old problem: ASSET open-label extensionFrancesco Del Galdo
European Journal of Rheumatology|July 23, 2020
Biomarkers as an opportunity to stratify for outcome in systemic sclerosisGiuseppina Abignano, Francesco Del Galdo
Current Rheumatology Reports|January 21, 2014
Quantitating skin fibrosis: innovative strategies and their clinical implicationsGiuseppina Abignano, Francesco Del Galdo
Annals of the Rheumatic Diseases|November 22, 2013
The search for the perfect animal model discloses the importance of biological targets for the treatment of systemic sclerosisFrancesco Del Galdo, Marco Matucci-Cerinic
Current Rheumatology Reports|March 30, 2006
T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunitiesFrancesco Del Galdo, Carol M Artlett
Arthritis and Rheumatism|October 2, 2007
T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitroFrancesco Del Galdo, Sergio A Jiménez
RMD Open|July 1, 2025
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025Cristiana Sieiro Santos, Francesco Del Galdo
European Journal of Rheumatology|November 9, 2020
A special European Journal of Rheumatology issue on systemic sclerosis: What and why?Francesco Del Galdo, Marco Matucci-Cerinic
The Lancet. Rheumatology|January 24, 2024
Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trialsFrancesco Del Galdo, Collette Hartley, Yannick Allanore
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
Cell Cycle (Georgetown, Tex.)|November 5, 2011
Caveolin-1: a new therapeutic target in tissue fibrosis and scleroderma?Francesco Del Galdo
The Lancet. Rheumatology|January 26, 2024
New lessons for an old problem: ASSET open-label extensionFrancesco Del Galdo
European Journal of Rheumatology|July 23, 2020
Biomarkers as an opportunity to stratify for outcome in systemic sclerosisGiuseppina Abignano, Francesco Del Galdo
Current Rheumatology Reports|January 21, 2014
Quantitating skin fibrosis: innovative strategies and their clinical implicationsGiuseppina Abignano, Francesco Del Galdo
Annals of the Rheumatic Diseases|November 22, 2013
The search for the perfect animal model discloses the importance of biological targets for the treatment of systemic sclerosisFrancesco Del Galdo, Marco Matucci-Cerinic
Current Rheumatology Reports|March 30, 2006
T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunitiesFrancesco Del Galdo, Carol M Artlett
Arthritis and Rheumatism|October 2, 2007
T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitroFrancesco Del Galdo, Sergio A Jiménez
RMD Open|July 1, 2025
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025Cristiana Sieiro Santos, Francesco Del Galdo
European Journal of Rheumatology|November 9, 2020
A special European Journal of Rheumatology issue on systemic sclerosis: What and why?Francesco Del Galdo, Marco Matucci-Cerinic
The Lancet. Rheumatology|January 24, 2024
Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trialsFrancesco Del Galdo, Collette Hartley, Yannick Allanore
Pageof 21